Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionet TherapeuticsROCO:7808 +2.42%20 Receivables Turnover is 3.99 as of Jun. 2026. GuruFocus rates ROCO:7808 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 852 Biotechnology companies, Bionet Therapeutics ranks better than 74.3% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bionet Therapeutics's Revenue for the
six
months ended in Jun. 2026 was NT$104.5 Mil. Bionet Therapeutics's average Accounts Receivable for the
six
months ended in Jun. 2026 was NT$26.2 Mil.
Hence, Bionet Therapeutics's Receivables Turnover for the
six
months ended in Jun. 2026 was 3.99.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bionet Therapeutics Receivables Turnover Related Terms
Bionet Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Bionet Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7808 vs VRTX, REGN, MRNA: Receivables Turnover Comparison
For the Biotechnology subindustry, Bionet Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionet Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bionet Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bionet Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionet Therapeutics (ROCO:7808) has a Receivables Turnover of 3.99 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bionet Therapeutics and its competitors. According to the industry distribution chart, Bionet Therapeutics ranks #219 out of 852 companies in the Biotechnology industry, placing it in the top 25.7%.
Is Bionet Therapeutics' Receivables Turnover too high?
Bionet Therapeutics' current Receivables Turnover is 3.99. The Biotechnology industry median Receivables Turnover is 5.28. Bionet Therapeutics' value of 3.99 is 24.4% below this industry median. Based on the distribution chart, Bionet Therapeutics ranks #219 out of 852 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bionet Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bionet Therapeutics ranks #219 out of 852 companies for Receivables Turnover. This puts Bionet Therapeutics in the upper half of its industry. The industry median Receivables Turnover is 5.28. Bionet Therapeutics' value of 3.99 is 24.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionet Therapeutics's current Receivables Turnover of 3.99 is 24.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bionet Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionet Therapeutics's current Receivables Turnover is 3.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current Receivables Turnover of 3.99. The current Receivables Turnover is 3.99 and 24.4% below the Biotechnology industry median of 5.28. Bionet Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current Receivables Turnover is 3.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
20GF Score
Get the complete analysis for ROCO:7808
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7808 has been successfully added to your 
